189 related articles for article (PubMed ID: 28760736)
1. Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression.
Sha S; Yuan D; Liu Y; Han B; Zhong N
Biol Open; 2017 Sep; 6(9):1310-1316. PubMed ID: 28760736
[TBL] [Abstract][Full Text] [Related]
2. LncRNA DANCR contributes to tumor progression via targetting miR-216a-5p in breast cancer: lncRNA DANCR contributes to tumor progression.
Tao W; Wang C; Zhu B; Zhang G; Pang D
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910842
[TBL] [Abstract][Full Text] [Related]
3. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR
Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442
[TBL] [Abstract][Full Text] [Related]
4. The role of FOXC1/FOXCUT/DANCR axis in triple negative breast cancer: a bioinformatics and experimental approach.
Kamaliyan Z; Mirfakhraie R; Azizi-Tabesh G; Darbeheshti F; Omranipour R; Ahmadinejad N; Zokaei E; Yassaee VR
Mol Biol Rep; 2022 Apr; 49(4):2821-2829. PubMed ID: 35066769
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA DANCR is activated by SALL4 and promotes the proliferation and invasion of gastric cancer cells.
Pan L; Liang W; Gu J; Zang X; Huang Z; Shi H; Chen J; Fu M; Zhang P; Xiao X; Qian H; Xu W; Jiang P; Zhang X
Oncotarget; 2018 Jan; 9(2):1915-1930. PubMed ID: 29416741
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Efficacy of the Combination of RNAi of lncRNA DANCR with Chemotherapy to Treat Triple Negative Breast Cancer Using Magnetic Resonance Molecular Imaging.
Nicolescu C; Kim J; Sun D; Lu ZR
Bioconjug Chem; 2024 Mar; 35(3):381-388. PubMed ID: 38446033
[TBL] [Abstract][Full Text] [Related]
8. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
9. High serum exosomal long non-coding RNA DANCR expression confers poor prognosis in patients with breast cancer.
Shi W; Jin X; Wang Y; Zhang Q; Yang L
J Clin Lab Anal; 2022 Mar; 36(3):e24186. PubMed ID: 35150011
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt/β-catenin signaling pathway.
Tian W; Lei N; Guo R; Yuan Z; Chang L
Cancer Cell Int; 2020; 20():61. PubMed ID: 32123519
[TBL] [Abstract][Full Text] [Related]
11. MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27.
Ren YQ; Fu F; Han J
Med Sci Monit; 2015 May; 21():1297-303. PubMed ID: 25943633
[TBL] [Abstract][Full Text] [Related]
12. Silencing long non-coding RNA, differentiation antagonizing non-protein coding RNA promotes apoptosis and inhibits tumor growth in colon cancer.
Yang XJ; Zhao JJ; Chen WJ; Zhang GG; Wang W; Tao HC
Oncol Lett; 2018 Sep; 16(3):2865-2872. PubMed ID: 30127873
[TBL] [Abstract][Full Text] [Related]
13. Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications.
Wang M; Gu J; Zhang X; Yang J; Zhang X; Fang X
Front Cell Dev Biol; 2021; 9():753706. PubMed ID: 34722539
[TBL] [Abstract][Full Text] [Related]
14. ESM1 promotes triple-negative breast cancer cell proliferation through activating AKT/NF-κB/Cyclin D1 pathway.
Liu W; Yang Y; He B; Ma F; Sun F; Guo M; Zhang M; Dong Z
Ann Transl Med; 2021 Apr; 9(7):533. PubMed ID: 33987231
[TBL] [Abstract][Full Text] [Related]
15. Roles of MALAT1 in development and migration of triple negative and Her-2 positive breast cancer.
Xiping Z; Bo C; Shifeng Y; Feijiang Y; Hongjian Y; Qihui C; Binbin T
Oncotarget; 2018 Jan; 9(2):2255-2267. PubMed ID: 29416769
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
17. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
18. ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc.
Cheng Y; Lin L; Li X; Lu A; Hou C; Wu Q; Hu X; Zhou Z; Chen Z; Tang F
Cancer Cell Int; 2021 Jan; 21(1):32. PubMed ID: 33413403
[TBL] [Abstract][Full Text] [Related]
19. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
20. Imbalance in leptin-adiponectin levels and leptin receptor expression as chief contributors to triple negative breast cancer progression in Northeast India.
Sultana R; Kataki AC; Borthakur BB; Basumatary TK; Bose S
Gene; 2017 Jul; 621():51-58. PubMed ID: 28414093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
